2023 World Conference on Lung Cancer (Posters)-EP09.02. Combination Of EGFR-TKIs And Radiotherapy In Stage IV LUAD

EP09.02. Combination Of EGFR-TKIs And Radiotherapy In Stage IV LUAD - PDF(Slides)

Pdf Summary

A study was conducted to determine whether patients with stage IV lung adenocarcinoma (LUAD) who have specific genetic mutations would benefit from receiving radiotherapy in addition to EGFR-TKIs treatment. The study included 177 patients with stage IV LUAD who were treated with EGFR-TKIs and radiotherapy. The results showed that patients with either the 19-Del or exon 21-L858R mutations had similar clinical characteristics. The overall median overall survival (mOS) for all patients was 32.0 months. Multivariate analysis revealed that EGFR mutations and thoracic radiotherapy were independent predictors of OS. Subgroup analysis showed that patients with the 19-Del mutation had a higher mOS compared to those with the exon 21-L858R mutation who received EGFR-TKIs in addition to radiotherapy for bone metastasis or thoracic radiotherapy. However, there was no significant difference in mOS between the two groups for patients who received radiotherapy for brain metastasis. In conclusion, patients with stage IV LUAD harboring the 19-Del mutation had a significantly longer OS when treated with EGFR-TKIs and radiotherapy, despite no significant differences in clinical features between the two mutation groups.

Asset Subtitle

Shuai Liang

Meta Tag

Speaker Shuai Liang

Topic Metastatic NSCLC: Local Therapies - Integration With Systemic Therapies

Keywords

study

patients

stage IV lung adenocarcinoma

LUAD

genetic mutations

radiotherapy

EGFR-TKIs treatment

overall survival

19-Del mutation

exon 21-L858R mutation